The Priority Review

Tag

Transplant

1 story

  1. Clinical trials

    Event-free survival 0.557 on ravulizumab and 0.475 on placebo in transplant-associated TMA

    In the Phase 3 trial, with 64 participants analyzed on ravulizumab and 62 on placebo, the event-free survival proportion at Week 26 was 0.557 on ravulizumab and 0.475 on placebo, with a p-value of 0.6386. Alexion's full results for this HSCT-TMA study are now public.